Corona Remedies Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹12.8K Cr
CORONA Remedies aims for **15% compound annual growth rate (CAGR) in revenue** over the next 3 to 4 years. CORONA Remedies targets a **15% CAGR revenue growth** over the next 3 to 4 years.
From Corona Remedies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,143
Market Cap
₹12.8K Cr
P/E Ratio
60.6
How does Corona Remedies Ltd rank in Pharmaceuticals & Biotechnology?
Compare Corona Remedies Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Corona Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹353 Cr, net profit ₹45 Cr.
Full financials →📊 Revenue & Sales Performance
- →CORONA Remedies aims for **15% compound annual growth rate (CAGR) in revenue** over the next 3 to 4 years.
- →The target for **profit after tax (PAT) or earnings per share (EPS) growth is around 20% year-on-year** for the next 3 to 4 years.
- →Revenue growth is generally steady with minor seasonal variations; Q3 sees slightly less growth due to festive season.
- →The company plans to expand its sales force by **5-7% annually**, supporting growth and new therapy launches.
- →Expansion into new therapies like infertility, spine, rheumatoid, CNS, dermatology, and gastrointestinal is expected to drive additional growth.
- →International business is in early stages but aims to contribute with hormonal products post plant commissioning, targeting higher single-digit contribution in a couple of years.
📈 Profitability & Margins
- →CORONA Remedies targets a **15% CAGR revenue growth** over the next 3 to 4 years.
- →The company aims for **20% PAT (Profit After Tax) or EPS (Earnings Per Share) growth** annually over the same period.
- →Management's endeavor is to sustain about **22%-23% margin bank** for FY '27 with potential reinvestment in marketing or field force.
- →The firm's plan includes a consistent expansion of medical representatives by **5%-7% annually** to support growth.
- →The new hormonal product plant is expected to contribute to international revenues starting FY '28, helping boost overall growth.
- →Profitability improvements are steady, with PAT margin fluctuations around 100 basis points quarter-on-quarter historically.
- →The focus on chronic therapies and specialist segments supports enhanced margins and sustainable profit growth.
🏗️ Capital Expenditure Plans
- →CORONA Remedies is investing in a new hormonal manufacturing plant in Ahmedabad, which has received the state Schedule M license and is expected to commence commercial production by Q2-end or early Q3 of FY '27.
- →The company aims to obtain WHO and EU GMP certifications for this plant by the end of FY '27 to ramp up its international hormonal products business.
- →There is a significant solar power investment: an existing 1.3 MW solar plant at Bhayla and a planned 4.25 MW solar park covering 11.9 acres, aimed at reducing electricity costs and supporting ESG initiatives.
- →CORONA is actively evaluating inorganic growth opportunities via M&A and in-licensing but remains selective, focusing on strategic fit and brand alignment rather than solely company origin.
- →The focus is on expanding marketing and field force by 5-7% annually to support growth and new therapy launches, indirectly requiring investment in human capital.
💰 Fundraising & Capital Structure
- →The transcript does not mention any current or planned fundraising through equity.
- →There is no explicit discussion about raising debt in the call.
- →Focus appears to be on organic growth and limited acquisitions (small acquisition from Bayer-Zydus done recently around INR 7.5-8 crores).
- →Plans include expanding manufacturing capacity, launching new therapies, and increasing marketing force funded through internal accruals.
- →No direct indication of external fundraising through either debt or equity in the immediate or near future.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Corona Remedies Ltd Q3 FY26 results?
CORONA Remedies aims for **15% compound annual growth rate (CAGR) in revenue** over the next 3 to 4 years. CORONA Remedies targets a **15% CAGR revenue growth** over the next 3 to 4 years.
What is Corona Remedies Ltd share price analysis?
Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.
Is Corona Remedies Ltd planning capital expenditure?
CORONA Remedies is investing in a new hormonal manufacturing plant in Ahmedabad, which has received the state Schedule M license and is expected to commence commercial production by Q2-end or early Q3 of FY '27.
Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.